ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 102 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.23 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $384,232 | -49.6% | 72,360 | -9.6% | 0.00% | – |
| Q2 2023 | $762,686 | -53.3% | 80,030 | -46.1% | 0.00% | -100.0% |
| Q1 2023 | $1,633,500 | +186.7% | 148,500 | +285.7% | 0.00% | – |
| Q4 2022 | $569,800 | +5.3% | 38,500 | +36.0% | 0.00% | – |
| Q3 2022 | $541,000 | -10.3% | 28,300 | 0.0% | 0.00% | – |
| Q2 2022 | $603,000 | +54.2% | 28,300 | +39.4% | 0.00% | – |
| Q1 2022 | $391,000 | -7.1% | 20,300 | 0.0% | 0.00% | – |
| Q4 2021 | $421,000 | -6.2% | 20,300 | +8.0% | 0.00% | – |
| Q3 2021 | $449,000 | -12.5% | 18,800 | 0.0% | 0.00% | – |
| Q2 2021 | $513,000 | +29.5% | 18,800 | +37.2% | 0.00% | – |
| Q1 2021 | $396,000 | -10.8% | 13,700 | -13.3% | 0.00% | – |
| Q4 2020 | $444,000 | -80.0% | 15,800 | -79.1% | 0.00% | -100.0% |
| Q3 2020 | $2,217,000 | -5.2% | 75,664 | -2.2% | 0.00% | 0.0% |
| Q2 2020 | $2,339,000 | +14.0% | 77,364 | +12.4% | 0.00% | 0.0% |
| Q1 2020 | $2,051,000 | – | 68,836 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
| Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
| Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
| Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
| AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
| Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
| Two Seas Capital LP | 164,807 | $875,125 | 0.18% |